Results 141 to 150 of about 2,927,324 (266)

Developing general practitioner and consumer supports for genomics in Australian primary care: a mixed-methods protocol. [PDF]

BMJ Open
Long JC, Archibald AD, Lamprell K, Dawson-McClaren B, Kraan C, Springer A, Dive L, Newson AJ, Watts G, Holmes I, Cutler H, Jeet V, Trainer A, Best S, Delatycki M, Kirk EP, Laing N, Ferrie M, Freeman L, Willcock S, Spanos S, Gilkes L, Cini J, Edwards S, Leibowitz R, Mahadeva J, Foo D, Churruca K, Patel R, Braithwaite J.   +29 more
europepmc   +1 more source

Spatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers

Molecular Oncology, EarlyView.
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur, Joel Rodrigues Vitória, Manuel Saiselet, Ligia Craciun, Denis Larsimont, Anne Lefort, Frédérick Libert, Carine Maenhaut, Sabine Costagliola, Maxime Tarabichi, Mirian Romitti, Vincent Detours   +11 more
wiley   +1 more source

Science Outreach: Providing an Authentic Independent Research Opportunity in Materials Science to School Students. [PDF]

J Chem Educ
Garrido N, Lee AJ, Turnbull C, Actis P, Rouncefield-Swales A.   +4 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

The way we do things matters: the deep integration of lived experience in the a/part of the crowd project to respond to loneliness in young adults. [PDF]

Res Involv Engagem
Peart C, Lewis M, Bibb J, Read G, Tesfu K, Rathore K, Tan LX, Wong T, Turner A, Andalib F, Ziero G, Rule J, Cao L, Merritt L, Rezaie N, Shelton T, Kaylor-Hughes C, Coe A, Orcher Muruwori/Gumbaynggirr P, Palmer VJ.   +19 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Employment after spinal cord injury in the United States: predictors and barriers. [PDF]

Front Rehabil Sci
Theotokatos G, Sadowsky C, Inches S, Morrow MM, Furtado M, Burns LR, Escorpizo R.   +6 more
europepmc   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Co-designing laryngectomy accessible information to support the development of an education and training package for community healthcare professionals: experiences and reflections from multiple stakeholders. [PDF]

Res Involv Engagem
Watson LJ, Wadey W, Babb M, Risi D, Waterston D, Barrass S, Sharp L, Hamilton DW, Thornton V, Patterson JM.   +9 more
europepmc   +1 more source